Fibralign Corporation

Fibralign Corporation is a Stanford-spinout, commercial-stage biomedical device manufacturer specializing in novel therapeutic scaffolds for lymphatic and soft tissue repair. The company's flagship product, BioBridge Collagen Matrix, is an FDA 510(k)-cleared Class II device for soft tissue repair and CE-marked Class III device for surgical treatment of secondary lymphedema. BioBridge has been deployed in over 750 surgeries across 19 countries and has regulatory approval in the US, Europe, South Korea, and the Middle East. The product is a thread-like collagen scaffold designed to repair damaged lymphatic tissue based on preclinical and clinical evidence. Fibralign is developing a proprietary Nanoweave® technology platform—a 3D scaffolding technology that mimics human tissue nanostructure to direct the body's repair mechanisms—enabling a pipeline of future products across multiple high-value therapeutic applications. The company collaborates with leading international surgeons and medical institutions, including participation in the International Society of Lymphology symposia. Fibralign targets the unmet medical need in secondary lymphedema treatment, a global chronic disease without current curative options, and positions itself for broader tissue engineering applications through its Nanoweave platform.